Chemokine programming of T cell responses could offer new drug targets.
Kathryn
K
Senior
D019380:Anti-HIV Agents / Q000627:therapeutic use; D001596:Benzylamines; D065100:CCR5 Receptor Antagonists; D019742:Chemokines, CC / Q000302:isolation & purification / Q000502:physiology*; D000080027:Cyclams; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D006801:Humans; D019713:Receptors, CCR5 / Q000502:physiology; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors* / Q000502:physiology; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends; D018417:Th1 Cells / Q000187:drug effects* / Q000502:physiology
D019380:Anti-HIV Agents; D001596:Benzylamines; D065100:CCR5 Receptor Antagonists; D019742:Chemokines, CC; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; C088327:plerixafor